Symbols / SXTP $2.34 +4.00%
SXTP Chart
About
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.01M |
| Enterprise Value | 7.90M | Income | -8.48M | Sales | 1.36M |
| Book/sh | -5.01 | Cash/sh | 3.89 | Dividend Yield | — |
| Payout | 0.00% | Employees | 3 | IPO | — |
| P/E | — | Forward P/E | -0.30 | PEG | — |
| P/S | 2.21 | P/B | -0.47 | P/C | — |
| EV/EBITDA | -1.01 | EV/Sales | 5.79 | Quick Ratio | 2.18 |
| Current Ratio | 2.87 | Debt/Eq | 3.54 | LT Debt/Eq | — |
| EPS (ttm) | -3.10 | EPS next Y | -7.88 | EPS Growth | — |
| Revenue Growth | 256.90% | Earnings | 2025-11-13 13:00 | ROA | -70.04% |
| ROE | -154.77% | ROIC | — | Gross Margin | 42.92% |
| Oper. Margin | -4.40% | Profit Margin | 0.00% | Shs Outstand | 1.29M |
| Shs Float | 937.14K | Short Float | 7.56% | Short Ratio | 0.30 |
| Short Interest | — | 52W High | 17.68 | 52W Low | 1.36 |
| Beta | 3.03 | Avg Volume | 4.67M | Volume | 244.63K |
| Target Price | $17.60 | Recom | None | Prev Close | $2.25 |
| Price | $2.34 | Change | 4.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$17.60
Mean price target
2. Current target
$2.25
Latest analyst target
3. DCF / Fair value
$-55.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.25
Low
$11.20
High
$24.00
Mean
$17.60
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-27 | main | HC Wainwright & Co. | Buy → Buy | $24 |
| 2025-11-28 | main | Ascendiant Capital | Buy → Buy | $3 |
| 2025-09-03 | main | Ascendiant Capital | Buy → Buy | $3 |
| 2025-06-02 | main | Ascendiant Capital | Buy → Buy | $7 |
| 2025-03-28 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-02-25 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-01-10 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-23 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-11 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-15 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-09-13 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-08-15 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-06-06 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-04-03 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2023-10-20 | init | HC Wainwright & Co. | — → Neutral | — |
| 2023-10-02 | init | Ascendiant Capital | — → Buy | $2 |
- 60 Degrees (SXTP) updates ATM capacity to $565K after prior sales - Stock Titan Fri, 13 Mar 2026 21
- 60 Degrees Pharmaceuticals Updates Opinion for ATM Program - The Globe and Mail Fri, 13 Mar 2026 21
- Market Movers | Winners: ACXP, SAFX, SXTP | Losers: CODX, QNTM, KITT - Trefis hu, 12 Mar 2026 08
- Dow, 60 degrees Pharmaceuticals CEO, buys $12k in SXTP stock - Investing.com Fri, 12 Dec 2025 08
- $SXTP stock is up 8% today. Here's what we see in our data. - Quiver Quantitative Wed, 28 Jan 2026 08
- Here's Why 60 Degrees Pharmaceuticals Inc. (SXTP) Looks Ripe for Bottom Fishing - Yahoo Finance ue, 23 Dec 2025 08
- 60 Degrees Pharmaceuticals files updated legal opinion confirming ATM program share validity - TradingView Fri, 13 Mar 2026 21
- 60 Degrees Pharmaceuticals Updates Legal Opinion for ATM Offering - TipRanks Fri, 13 Mar 2026 21
- SXTP Stock Rockets 161% Pre-Market — What Is Driving The Surge? - Stocktwits Fri, 23 Jan 2026 08
- [424B5] 60 DEGREES PHARMACEUTICALS, INC. Prospectus Supplement (Debt Securities) - Stock Titan Wed, 11 Mar 2026 21
- Here’s Why 60 Degrees Pharmaceuticals Stock (SXTP) Rocketed Today - TipRanks hu, 22 Jan 2026 08
- 60 Degrees Pharmaceuticals stock soars on new telehealth partnership - Investing.com hu, 22 Jan 2026 08
- In tiny trial, malaria drug combo cleared a stubborn tick-borne infection - Stock Titan Wed, 11 Mar 2026 11
- 60 Degrees Pharmaceuticals files updated legal opinion for ATM equity program - Investing.com Fri, 13 Mar 2026 22
- Nasdaq-listed 60 Degrees Pharma shrinks shares 4-for-1 on Jan. 20 reverse - Stock Titan hu, 15 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 9670 | 7759.0 | — | Purchase at price 0.80 per share. | DOW GEOFFREY S | Chief Executive Officer | — | 2025-12-15 00:00:00 | D |
| 1 | 12963 | 12204.0 | — | Purchase at price 0.92 - 0.95 per share. | DOW GEOFFREY S | Chief Executive Officer | — | 2025-12-11 00:00:00 | D |
| 2 | 7201 | 9996.0 | — | Stock Award(Grant) at price 1.39 per share. | DOW GEOFFREY S | Chief Executive Officer | — | 2025-09-12 00:00:00 | D |
| 3 | 4376 | 13065.0 | — | Stock Award(Grant) at price 2.99 per share. | DOW GEOFFREY S | Chief Executive Officer | — | 2025-06-09 00:00:00 | D |
| 4 | 5000 | 14410.0 | — | Purchase at price 2.87 - 2.90 per share. | XU CHERYL | Director | — | 2025-06-03 00:00:00 | D |
| 5 | 14394 | nan | — | — | DOW GEOFFREY S | Chief Executive Officer | — | 2025-01-17 00:00:00 | D |
| 6 | 11626 | nan | — | — | MILLER TYRONE | Chief Financial Officer | — | 2025-01-17 00:00:00 | D |
| 7 | 4540 | nan | — | — | LANDON KRISTEN | Chief Operating Officer | — | 2025-01-17 00:00:00 | D |
| 8 | 13000 | 21400.0 | — | Purchase at price 1.45 - 1.85 per share. | XU CHERYL | Director | — | 2024-12-16 00:00:00 | D |
| 9 | 73951 | 89755.0 | — | Purchase at price 1.11 - 1.27 per share. | DOW GEOFFREY S | Chief Executive Officer | — | 2024-12-09 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -350.38K | -82.79K | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -9.55M | 241.94K | -1.71M | -1.01M |
| TotalUnusualItems | 1.67M | -1.67M | -394.24K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 1.67M | -1.67M | -394.24K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.95M | -3.77M | -6.18M | -4.25M |
| ReconciledDepreciation | 63.74K | 100.37K | 78.79K | 71.78K |
| ReconciledCostOfRevenue | 384.76K | 474.55K | 432.37K | 850.74K |
| EBITDA | -7.88M | -1.43M | -2.11M | -1.01M |
| EBIT | -7.95M | -1.53M | -2.19M | -1.09M |
| NetInterestIncome | -7.91K | -2.29M | -3.99M | -3.17M |
| InterestExpense | 7.91K | 2.29M | 3.99M | 3.17M |
| NormalizedIncome | -9.61M | -2.45M | -5.87M | -4.25M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.95M | -3.77M | -6.18M | -4.25M |
| TotalExpenses | 10.32M | 5.41M | 1.97M | 2.28M |
| TotalOperatingIncomeAsReported | -9.71M | -5.15M | -1.75M | -1.12M |
| DilutedAverageShares | 113.64K | 16.58K | 23.21K | 23.21K |
| BasicAverageShares | 113.64K | 16.58K | 23.21K | 23.21K |
| DilutedEPS | -74.20 | -236.72 | -266.38 | -183.22 |
| BasicEPS | -74.20 | -236.72 | -266.38 | -183.22 |
| DilutedNIAvailtoComStockholders | -7.95M | -3.77M | -6.18M | -4.25M |
| NetIncomeCommonStockholders | -7.95M | -3.77M | -6.18M | -4.25M |
| NetIncome | -7.95M | -3.77M | -6.18M | -4.25M |
| MinorityInterests | 8.56K | 48.10K | -3.94K | 8.55K |
| NetIncomeIncludingNoncontrollingInterests | -7.96M | -3.81M | -6.18M | -4.26M |
| NetIncomeContinuousOperations | -7.96M | -3.81M | -6.18M | -4.26M |
| TaxProvision | 250.00 | 250.00 | 500.00 | 1.00K |
| PretaxIncome | -7.96M | -3.81M | -6.18M | -4.26M |
| OtherIncomeExpense | 1.77M | 3.63M | -437.48K | 37.52K |
| OtherNonOperatingIncomeExpenses | 101.46K | 5.30M | -43.24K | 37.52K |
| SpecialIncomeCharges | 0.00 | -1.23M | 120.68K | 0.00 |
| OtherSpecialCharges | 1.23M | -120.68K | ||
| GainOnSaleOfSecurity | 1.67M | -437.00K | -514.92K | |
| NetNonOperatingInterestIncomeExpense | -7.91K | -2.29M | -3.99M | -3.17M |
| InterestExpenseNonOperating | 7.91K | 2.29M | 3.99M | 3.17M |
| OperatingIncome | -9.71M | -5.15M | -1.75M | -1.12M |
| OperatingExpense | 9.94M | 4.93M | 1.54M | 1.43M |
| OtherOperatingExpenses | -73.77K | -288.00K | -5.19M | |
| ResearchAndDevelopment | 4.99M | 691.77K | 525.56K | 5.51M |
| SellingGeneralAndAdministration | 5.02M | 4.24M | 1.30M | 1.12M |
| GeneralAndAdministrativeExpense | 5.02M | 4.24M | 1.30M | 1.12M |
| OtherGandA | 5.02M | 4.24M | 1.30M | 1.12M |
| GrossProfit | 222.81K | -220.98K | -209.16K | 309.60K |
| CostOfRevenue | 384.76K | 474.55K | 432.37K | 850.74K |
| TotalRevenue | 607.57K | 253.57K | 223.21K | 1.16M |
| OperatingRevenue | 607.57K | 253.57K | 223.21K | 1.16M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 141.73K | 24.21K | 23.21K | 23.21K |
| ShareIssued | 141.73K | 24.21K | 23.21K | 23.21K |
| NetDebt | 22.14M | 18.63M | ||
| TotalDebt | 155.89K | 172.67K | 22.42M | 18.80M |
| TangibleBookValue | -5.69M | -5.22M | -23.74M | -17.69M |
| InvestedCapital | -5.38M | -4.83M | -1.17M | 1.17M |
| WorkingCapital | 3.73M | 4.41M | -22.82M | 541.20K |
| NetTangibleAssets | 3.88M | 4.64M | -23.74M | -17.69M |
| CapitalLeaseObligations | 0.00 | 13.65K | 13.00K | 59.80K |
| CommonStockEquity | -5.53M | -4.99M | -23.58M | -17.58M |
| PreferredStockEquity | 9.57M | 9.86M | ||
| TotalCapitalization | 4.18M | 5.02M | -22.31M | 1.17M |
| TotalEquityGrossMinorityInterest | 3.96M | 4.80M | -24.15M | -18.15M |
| MinorityInterest | -80.59K | -72.04K | -572.32K | -576.26K |
| StockholdersEquity | 4.04M | 4.87M | -23.58M | -17.58M |
| GainsLossesNotAffectingRetainedEarnings | 135.47K | 135.56K | 73.71K | 75.83K |
| OtherEquityAdjustments | 135.47K | 135.56K | 73.71K | 75.83K |
| RetainedEarnings | -40.53M | -32.58M | -28.82M | -22.63M |
| AdditionalPaidInCapital | 34.86M | 27.46M | 5.16M | 0.00 |
| CapitalStock | 9.57M | 9.86M | 239.00 | 4.98M |
| CommonStock | 57.00 | 10.00 | 239.00 | 4.98M |
| PreferredStock | 9.57M | 9.86M | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.80M | 2.99M | 25.45M | 19.55M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 147.12K | 150.25K | 1.53M | 18.91M |
| DuetoRelatedPartiesNonCurrent | 0.00 | |||
| TradeandOtherPayablesNonCurrent | 0.00 | |||
| NonCurrentDeferredLiabilities | 0.00 | 255.00K | 154.74K | |
| NonCurrentDeferredRevenue | 0.00 | 255.00K | 154.74K | |
| LongTermDebtAndCapitalLeaseObligation | 147.12K | 150.25K | 1.27M | 18.76M |
| LongTermCapitalLeaseObligation | 0.00 | 13.00K | ||
| LongTermDebt | 147.12K | 150.25K | 1.27M | 18.74M |
| CurrentLiabilities | 1.66M | 2.84M | 23.92M | 635.47K |
| OtherCurrentLiabilities | 640.83K | 2.31M | 1.49M | 3.13K |
| CurrentDeferredLiabilities | 0.00 | 325.00K | 0.00 | |
| CurrentDeferredRevenue | 0.00 | 325.00K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 8.77K | 22.42K | 21.15M | 46.80K |
| CurrentCapitalLeaseObligation | 0.00 | 13.65K | 13.00K | 46.80K |
| CurrentDebt | 8.77K | 8.77K | 21.14M | |
| OtherCurrentBorrowings | 8.77K | 8.77K | 16.86M | |
| CurrentNotesPayable | 0.00 | 4.28M | 0.00 | |
| PayablesAndAccruedExpenses | 1.01M | 506.21K | 953.76K | 588.68K |
| Payables | 1.01M | 506.21K | 953.76K | 588.68K |
| OtherPayable | 47.09K | |||
| DuetoRelatedPartiesCurrent | 0.00 | 195.10K | 0.00 | |
| TotalTaxPayable | 1.00K | |||
| IncomeTaxPayable | 1.00K | |||
| AccountsPayable | 1.01M | 506.21K | 758.67K | 588.68K |
| TotalAssets | 5.76M | 7.78M | 1.30M | 1.39M |
| TotalNonCurrentAssets | 373.07K | 541.18K | 198.20K | 216.85K |
| NonCurrentPrepaidAssets | 66.18K | 242.65K | 0.00 | 6.03K |
| GoodwillAndOtherIntangibleAssets | 157.08K | 227.26K | 164.25K | 109.24K |
| OtherIntangibleAssets | 157.08K | 227.26K | 164.25K | 109.24K |
| NetPPE | 149.81K | 71.28K | 33.95K | 107.61K |
| AccumulatedDepreciation | -149.43K | -148.06K | -126.90K | -99.25K |
| GrossPPE | 299.24K | 219.34K | 160.85K | 206.87K |
| OtherProperties | 233.41K | 146.43K | 145.56K | 191.58K |
| MachineryFurnitureEquipment | 65.83K | 72.91K | 15.29K | 15.29K |
| CurrentAssets | 5.39M | 7.24M | 1.10M | 1.18M |
| OtherCurrentAssets | 1.07M | 4.40M | 200.97K | 225.87K |
| CurrentDeferredAssets | 1.73M | 0.00 | 68.63K | 0.00 |
| PrepaidAssets | 200.97K | 225.87K | ||
| Inventory | 442.76K | 466.17K | 518.58K | 689.04K |
| InventoriesAdjustmentsAllowances | 0.00 | -160.34K | -38.32K | |
| FinishedGoods | 157.88K | 187.18K | 183.94K | 37.51K |
| WorkInProcess | 284.88K | 278.99K | 97.49K | 88.47K |
| RawMaterials | 0.00 | 397.49K | 601.38K | |
| Receivables | 486.75K | 231.33K | 45.97K | 146.36K |
| AccountsReceivable | 486.75K | 231.33K | 45.97K | 146.36K |
| CashCashEquivalentsAndShortTermInvestments | 1.66M | 2.14M | 264.87K | 115.40K |
| CashAndCashEquivalents | 1.66M | 2.14M | 264.87K | 115.40K |
| CashFinancial | 1.66M | 2.14M | 264.87K | 115.40K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -5.83M | -4.66M | -1.07M | -684.50K |
| RepaymentOfDebt | 0.00 | -1.61M | 0.00 | -72.00K |
| IssuanceOfDebt | 0.00 | 650.00K | 1.10M | 683.23K |
| IssuanceOfCapitalStock | 7.04M | 6.30M | 0.00 | |
| CapitalExpenditure | -181.11K | -115.89K | -60.13K | -35.39K |
| InterestPaidSupplementalData | 8.77K | 179.12K | 2.19K | 0.00 |
| IncomeTaxPaidSupplementalData | 2.00K | 1.00K | 1.00K | 750.00 |
| EndCashPosition | 1.66M | 2.14M | 264.87K | 115.40K |
| BeginningCashPosition | 2.14M | 264.87K | 115.40K | 191.70K |
| EffectOfExchangeRateChanges | 499.00 | 61.85K | -2.13K | -3.03K |
| ChangesInCash | -483.63K | 1.82M | 151.59K | -73.27K |
| FinancingCashFlow | 7.05M | 6.47M | 1.22M | 611.23K |
| CashFlowFromContinuingFinancingActivities | 7.05M | 6.47M | 1.22M | 611.23K |
| NetOtherFinancingCharges | -150.42K | 116.71K | ||
| ProceedsFromStockOptionExercised | 10.96K | 1.13M | 0.00 | |
| NetCommonStockIssuance | 7.04M | 6.30M | 0.00 | |
| CommonStockIssuance | 7.04M | 6.30M | 0.00 | |
| NetIssuancePaymentsOfDebt | 0.00 | -961.11K | 1.10M | 611.23K |
| NetLongTermDebtIssuance | 0.00 | -961.11K | 1.10M | 611.23K |
| LongTermDebtPayments | 0.00 | -1.61M | 0.00 | -72.00K |
| LongTermDebtIssuance | 0.00 | 650.00K | 1.10M | 683.23K |
| InvestingCashFlow | -1.89M | -115.89K | -60.13K | -35.39K |
| CashFlowFromContinuingInvestingActivities | -1.89M | -115.89K | -60.13K | -35.39K |
| NetInvestmentPurchaseAndSale | -1.71M | 0.00 | ||
| PurchaseOfInvestment | -1.71M | 0.00 | ||
| NetIntangiblesPurchaseAndSale | -25.37K | -18.28K | -27.07K | 0.00 |
| PurchaseOfIntangibles | -25.37K | -18.28K | -27.07K | 0.00 |
| NetPPEPurchaseAndSale | -103.77K | -57.62K | 0.00 | -3.07K |
| PurchaseOfPPE | -103.77K | -57.62K | 0.00 | -3.07K |
| CapitalExpenditureReported | -51.97K | -39.98K | -33.06K | -32.32K |
| OperatingCashFlow | -5.65M | -4.54M | -1.01M | -649.11K |
| CashFlowFromContinuingOperatingActivities | -5.65M | -4.54M | -1.01M | -649.11K |
| ChangeInWorkingCapital | 192.72K | 405.36K | 3.37M | 2.90M |
| ChangeInOtherWorkingCapital | -100.00K | 425.26K | 51.73K | |
| ChangeInOtherCurrentLiabilities | -13.65K | -50.27K | -46.80K | -39.82K |
| ChangeInPayablesAndAccruedExpense | 477.81K | 1.05M | 2.86M | 1.72M |
| ChangeInAccruedExpense | -23.60K | 1.27M | 2.69M | 2.57M |
| ChangeInInterestPayable | -23.60K | 1.27M | 2.69M | |
| ChangeInPayable | 501.41K | -214.73K | 169.99K | -844.67K |
| ChangeInAccountPayable | 501.41K | -214.73K | 169.99K | -844.67K |
| ChangeInPrepaidAssets | -39.42K | -522.37K | 24.90K | 135.84K |
| ChangeInInventory | 23.41K | 212.75K | 10.13K | 312.23K |
| ChangeInReceivables | -255.42K | -185.37K | 100.40K | 713.06K |
| ChangesInAccountReceivables | -255.42K | -185.37K | 100.40K | 713.06K |
| OtherNonCashItems | -4.48M | 1.16M | 604.60K | |
| StockBasedCompensation | 3.61M | 1.74M | 0.00 | |
| ProvisionandWriteOffofAssets | 0.00 | -160.34K | 160.34K | 38.32K |
| AssetImpairmentCharge | 108.42K | 0.00 | ||
| DepreciationAmortizationDepletion | 63.74K | 100.37K | 78.79K | 71.78K |
| DepreciationAndAmortization | 63.74K | 100.37K | 78.79K | 71.78K |
| AmortizationCashFlow | 38.50K | 29.16K | 5.12K | 3.31K |
| AmortizationOfIntangibles | 38.50K | 29.16K | 5.12K | 3.31K |
| Depreciation | 25.24K | 71.22K | 73.67K | 68.47K |
| OperatingGainsLosses | -1.67M | 1.67M | 394.24K | |
| GainLossOnInvestmentSecurities | -1.67M | 437.00K | 514.92K | |
| NetIncomeFromContinuingOperations | -7.96M | -3.81M | -6.18M | -4.26M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SXTP
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|